uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130
uniQure’s AMT-130 gene therapy for Huntington’s disease has received Breakthrough Therapy designation from the FDA, adding to its existing...
Jon Napitupulu
Nurix’s Novel IRAK4 Degrader, GS-6791/NX-0479, Gets FDA Clearance
Nurix Therapeutics announced FDA clearance of the Investigational New Drug (IND) application for GS-6791/NX-0479, an IRAK4 degrader. This allows...
Promising Interim Results from Phase III Agalsidase Beta Study for Fabry Disease
Biosidus, an Argentinian biotechnology company, announced positive interim Phase III trial results for its agalsidase beta biosimilar for Fabry...
Sabin Launches Marburg Vaccine Trial in US
The Sabin Vaccine Institute initiated a Phase 2 clinical trial of its Marburg vaccine candidate in the United States,...
Sonnet Releases Positive Safety Data for SON-1010 in Phase 1b/2a
Sonnet BioTherapeutics announced positive safety data for SON-1010 (IL12-FHAB) at the highest dose combined with atezolizumab in a Phase...
BioVie Starts Bezisterim SUNRISE-PD Trial in Early Parkinson’s
BioVie Inc. has initiated patient enrollment for its Phase 2 SUNRISE-PD clinical trial. This trial investigates the safety and...
Briacell Phase 2 Data: HR+ Breast Cancer Breakthrough
BriaCell Therapeutics Corp. announced positive survival data from its Phase 2 study of Bria-IMT™ combined with checkpoint inhibitors in...
Cln-978: Groundbreaking RA Therapy Enters Phase 1 Trial
Cullinan Therapeutics announced that the European Medicines Agency (EMA) approved its Clinical Trial Application for CLN-978, a novel CD19xCD3...
Heparegenix Secures €21.5M for Liver Regeneration
HepaRegeniX, a clinical-stage company developing therapies for liver diseases, completed a €21.5 million financing round with Wellington Partners. The...
Promising Efficacy Reported for TLX101 Glioma Therapy
Telix Pharmaceuticals announced preliminary positive Phase 2 results for TLX101, a targeted radiation therapy for recurrent high-grade glioma (brain...